New hope for HHT nosebleeds: drug trial aims to stop the bleeding
Symptom relief
Recruiting now
This study tests whether the drug nintedanib can reduce the frequency and severity of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels. About 48 adults with moderate to severe nosebleeds will take either ninteda…
Phase: PHASE2 • Sponsor: Dr. Romain Lazor • Aim: Symptom relief
Last updated May 20, 2026 11:58 UTC